CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 200 enrolled
Drug / intervention
Bupropion +1 moredrug
Likely dose
Bupropion 150mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00687713
NCT00687713Phase 2Completed
CompareCT.gov

Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence

National Institute on Drug Abuse (NIDA)·interventional·Posted Jun 2, 2008·Updated Mar 21, 2017

In Brief

A Phase 2 clinical trial evaluating Bupropion and Placebo for Methamphetamine Dependence. Completed, enrolled 200 participants across 12 sites.

Detailed Summary

This study is to assess the efficacy of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence who report using methamphetamine 29 or less days during the 30 days prior to the start of signing consent.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMethamphetamine Dependence
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2, 2008
Enrollment StartMay 1, 2008
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 18.1 years ago

Interventions

Bupropiondrug

150mg for the first 3 days of dosing. Increased to 150 mg b.i.d until taper.

Placeboother

Placebo